Clinical Trials
2 trialsNCT01625234 2026-04-30
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Xcovery Holdings, Inc.
Phase 1/2 Completed
NCT07448116 2026-03-04
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Betta Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting